Invalidity dossier
US 10022379
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
Added 9/16/2026, 6:46:39 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 10022379 B2
Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation.
Patent number / application: US 10022379 B2; application US 15/403,705; pre-grant publication US 2017/0119773 A1.
Assignee: Boehringer Ingelheim International GmbH (original and current assignee, per the listing).
Key dates: Priority date 2008-04-03; filing date 2017-01-11; publication (grant) 2018-07-17. Listed status: Active; anticipated expiration 2029-04-02.
Inventors: Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi Maruyama, Takaaki Nishioka.
Purpose and plain-language scope: The patent concerns formulations that combine a DPP-IV inhibitor (a class of antidiabetic compound) with a further antidiabetic agent. The claims scope is directed to tablets containing such a combination, the use of those formulations, and a process for preparing them. The disclosed chemical structures center on xanthine-based DPP-IV inhibitors bearing a butynyl substituent and a piperidinyl-amino moiety — for example the compound depicted as CC#CCN1C(N2CCCC@@HC2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C (CID LTXREWYXXSTFRX-QGZVFWFLSA-N) — alongside other listed compounds and a further antidiabetic agent. International classification includes A61K45/06 (mixtures of active ingredients without chemical characterisation) and various A61K31/xx entries covering heterocyclic active ingredients, purines, and amidines/guanidines (consistent with a biguanide-type second agent).
The document also lists related later-filed US applications/patents (e.g., US 2018/0289716 A1; US 10,973,827 B2) and several US district court case references.
What this excerpt does not establish: It contains no claim text, so the precise metes and bounds of the claims cannot be stated. No examples, dosages, pharmacokinetic data, or worked manufacturing details appear. The excerpt does not establish validity, enforceability, ownership transfers, or the merits or outcome of any listed litigation, and it provides no prior-art analysis.
Generated 10/1/2026, 10:03:32 PM
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 10022379. The free-form analysis below may also discuss cases beyond this list.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.
Keep exploring
More patents asserted by Boehringer Ingelheim Pharmaceuticals Inc.
- US 9415016I'll search for authoritative information on US 9415016, including its claims and any 2026 CAFC docket activity. Let me look for the claim text of US 9415016 and any Federal Circuit activity. Let me try to retrieve the actual claim set…
- US 11911388Patent Overview: US11911388B2 Title: Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug Assignee: Boehringer Ingelheim International GmbH Key dates: Priority…
- US 10973827Patent Overview: US10973827B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Patent number: US10973827B2 | Application: US16/676,643 |…
- US 9155705Patent Overview: US 9,155,705 B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation. Assignee: Boehringer Ingelheim International GmbH…
This patent in court (1)
1 tracked lawsuit name US 10022379.